Back

Outpatient diuretic intensification, NT-proBNP and eGFR as early markers of disease progression in patients with ATTR-CM: a validation study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: light chain to transthyretin Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Awais Sheikh

National Amyloidosis Centre, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Sex differences in cardiac amyloidosis: a clustering-based analysis
Assistant Professor A. Zaroui (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Red blood cell distribution width and red blood cell distribution width/albumin ratio as predictors of mortality in light chain cardiac amyloidosis
Doctor X. Li (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Subtle elevations in carcinoembryonic antigen are associated with increased all-cause mortality in patients with light chain cardiac amyloidosis
Doctor X. Li (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of ventricular tachycardia characteristics in patients with light-chain cardiac amyloidosis
Doctor J. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Synthetic extracellular volume from myocardial radiomics to identify transthyretin cardiac amyloidosis from routinely acquired CT angiography scans
Assistant Professor A. Antonopoulos (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: light chain to transthyretin

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Outcome and disease progression in patients with wild-type transthyretin cardiomyopathy treated with tafamidis
thumbnail
Congress Presentation
Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis
thumbnail
Congress Presentation
Disease progression and outcomes in patients with transthyretin amyloid cardiomyopathy receiving tafamidis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources